Modality
Radioligand
MOA
SGLT2i
Target
DLL3
Pathway
mTOR
ADHDTTR AmyloidosisHeart Failure
Development Pipeline
Preclinical
Dec 2020
→ Dec 2028
PreclinicalCurrent
NCT03233604
756 pts·TTR Amyloidosis
2020-12→2028-12·Recruiting
NCT07518067
142 pts·Heart Failure
2022-02→2027-12·Terminated
898 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-12-181.7y awayInterim· Heart Failure
2028-12-222.7y awayInterim· TTR Amyloidosis
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Recruit…
Preclinical
Termina…
Catalysts
Interim
2027-12-18 · 1.7y away
Heart Failure
Interim
2028-12-22 · 2.7y away
TTR Amyloidosis
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03233604 | Preclinical | TTR Amyloidosis | Recruiting | 756 | SRI-4 |
| NCT07518067 | Preclinical | Heart Failure | Terminated | 142 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 |